Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangsu Hengrui Medicine Co. Ltd.

www.hrs.com.cn

Latest From Jiangsu Hengrui Medicine Co. Ltd.

China's Hengrui Halts Most Generic Development

China’s favorite domestic drug maker seems to have a warning for the industry - innovate or halt. After the recent round of “4+7” centralized procurement saw some off-patent drugs priced at pennies, the leading Chinese firm Hengrui has decided to halve its generics portfolio to focus on innovative new drugs.

China Strategy

Hengrui Halts Most Generic Development After Prices Free Fall In China

China’s favorite domestic drug maker seems to have a warning for the industry - innovate or halt. After the recent round of “4+7” centralized procurement saw some off-patent drugs priced at pennies, the leading Chinese firm Hengrui has decided to halve its generics portfolio to focus on innovative new drugs.

China Generic Drugs

Elevar Aims For Rivoceranib Turnaround After Positive Phase III Update

Despite failing to meet the primary endpoint in recent top-line Phase III results, Elevar Therapeutics (formerly LSK BioPharma) is hopeful that rivoceranib still has potential in late-stage gastric cancer based on generally positive full efficacy data from the global Phase III study presented at ESMO.

Clinical Trials Cancer

Oncology Dominates As China Drug, Biologic Approvals Surge

China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.

China Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Senior Management
  • Piaoyang Sun, Chmn.
    Lianshan Zhang, PhD, Pres., Global R&D
  • Contact Info
  • Jiangsu Hengrui Medicine Co. Ltd.
    Phone: 800 828 3900
    Lianyung Eco & Tech Development Zone
    7 Kunlunshan Rd
    , 222000
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register